MedTrace Logo

Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT06879782 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 820

Last updated 2025-03-17

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.

Conditions

  • Dry Eye Disease (DED)

Interventions

DRUG

Drug placebo

Instill one drop of the eye solution in each eye, twice a day (morning and evening, approximately 12 hours apart), for a treatment period of 12 weeks.

Sponsors & Collaborators

  • Beijing Tongren Hospital

    collaborator OTHER

  • Lunan Better Pharmaceutical Co., LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-28
Primary Completion
2026-03-28
Completion
2026-09-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06879782 on ClinicalTrials.gov